Aldehyde dehydrogenase-1a1 (ALDH1a1), the enzyme responsible for the oxidation of retinal into retinoic acid, represents a key therapeutic target for the treatment of debilitating disorders such as cancer, obesity, and inflammation. This evidence concerns the gene ALDH1A1 and obesity due to melanocortin 4 receptor deficiency.